NCT06154252Phase 2, phase 3Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Study sponsor: Cabaletta Bio

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-07Estimated
Enrollment · participants74Estimated
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate adverse events reported by subjects. After: Measure: Phase 1/2: Incidence and severity of adverse events (AEs) Measure: Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Measure: Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids.

Planned enrollment increased by 50 participants

Before: 24 participants (planned). After: 74 participants (planned).

Phase changed

Before: PHASE1, PHASE2. After: PHASE2, PHASE3.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview